Inhibikase Therapeutics Reveals New Company Presentation in Recent 8-K Filing

Inhibikase Therapeutics, Inc. (NYSE: IKT) disclosed in an 8-K filing to the Securities and Exchange Commission on October 9, 2024, the release of a fresh company presentation accessible on its investor relations website. The presentation, dated the same day, has been attached as Exhibit 99.1 to the filing.

The company’s Item 7.01 Regulation FD Disclosure section in the filing states that Inhibikase Therapeutics made available the new presentation on their website. However, it is important to note that the information shared in this presentation is not to be considered as “filed” under the Exchange Act’s Section 18, nor does it subject to the liabilities outlined in that section. Additionally, the contents of this particular 8-K filing are not integrated by reference into any past or future filings by the company under the Securities Act of 1933 or the Exchange Act, except if explicitly specified within those filings.

Furthermore, Item 9.01 of the filing indicates the disclosure of financial statements and exhibits, with the company presentation listed as Exhibit 99.1 and a Cover Page Interactive Data File embedded within the Inline XBRL document denoted as Exhibit 104.

The filing concludes with the necessary signatures, confirming that the report was signed on October 9, 2024, by Milton H. Werner, Ph.D., who serves as the President and Chief Executive Officer of Inhibikase Therapeutics, Inc.

This recent 8-K filing provides investors and stakeholders with crucial insights into the current activities and presentations of Inhibikase Therapeutics, allowing for a more comprehensive understanding of the company’s operations and strategic directions.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Inhibikase Therapeutics’s 8K filing here.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.